These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1025339)

  • 1. Recombinant influenza-virus vaccines: I. Rapid derivation and preliminary characterization of high-yielding recombinants of influenza virus.
    Higashihara M; Igarashi Y; Nakagawa S; Saito Y
    Kitasato Arch Exp Med; 1976 Jun; 49(1-2):1-26. PubMed ID: 1025339
    [No Abstract]   [Full Text] [Related]  

  • 2. Future influenza vaccines and the use of genetic recombinants.
    Kilbourne ED
    Bull World Health Organ; 1969; 41(3):643-5. PubMed ID: 5309489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant influenza-virus vaccines: II. Some properties of high-yielding recombinant influenza viruses and their vaccines.
    Higashihara M; Igarashi Y; Saito Y
    Kitasato Arch Exp Med; 1976 Jun; 49(1-2):27-41. PubMed ID: 1025340
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on genetic recombinants of influenza virus: fundamental studies on recombinant influenza-virus vaccines.
    Higashihara M
    Kitasato Arch Exp Med; 1975 Dec; 48(4):183-8. PubMed ID: 1234926
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant influenza-virus vaccines. III. Isolation and preliminary characterization of so-called antigenic recombinant influenza viruses.
    Higashihara M; Igarashi Y; Saito Y
    Kitasato Arch Exp Med; 1976 Sep; 49(3):67-79. PubMed ID: 1029758
    [No Abstract]   [Full Text] [Related]  

  • 6. Attenuated influenza B virus recombinants obtained by crossing of B/England/2608/76 virus with a cold-adapted B/Leningrad/14/17/55 strain.
    Medvedeva TE; Gordon MA; Ghendon YZ; Klimov AI; Alexandrova GI
    Acta Virol; 1983 Jul; 27(4):311-7. PubMed ID: 6195900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of influenza B virus recombinant strains.
    Podchernyaeva RYa ; Shchipanova MV; Elkin VS; Melnichenko EI
    Acta Virol; 1987 Nov; 31(6):475-80. PubMed ID: 2894141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High reproduction capacity of recombinants between H3N2 human influenza and fowl plague viruses is due to the gene coding for M proteins.
    Klimov A; Ghendon Y; Závadová H; Broucek J; Medvedeva T
    Acta Virol; 1983 Sep; 27(5):434-8. PubMed ID: 6139948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant influenza-virus vaccines. IV. Segregation of antigenic and some biological properties of Influenza virus neuraminidase by recombination.
    Higashihara M; Igarashi Y; Saito Y
    Kitasato Arch Exp Med; 1976 Sep; 49(3):81-91. PubMed ID: 1029759
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies of biological properties of the recombinants between human influenza and fowl plague viruses as related to genome composition.
    Ginzburg VP; Markushin SG; Ghendon YZ
    Acta Virol; 1982 Dec; 26(6):432-7. PubMed ID: 6132538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated ts-recombinants of influenza A/USSR/77 (H1N1) virus obtained by crossing with the cold-adapted donor A/Leningrad/134/57 (H2N2) virus.
    Polezhaev FI; Garmashova LM; Koval TA; Taranova GP; Topuriya NV; Aleksandrova GI
    Acta Virol; 1982 Jul; 26(4):221-6. PubMed ID: 6127928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Derivation of high-yielding influenza A virus recombinants for vaccine production (author's transl)].
    Higashihara M; Suzuki Y; Saito Y; Igarashi Y; Yoshioka I
    Uirusu; 1978 Jun; 28(1):46-8. PubMed ID: 695332
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peculiarities of obtaining attenuated thermosensitive recombinants of influenza A virus at the end of the H3N2 epidemic cycle.
    Polezhaev FI; Garmashova LM; Rumovsky VI; Aleksandrova GI; Smorodintsev AA
    Acta Virol; 1980 Jun; 24(4):273-8. PubMed ID: 6106378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies on influenza A2 virus infection after peroral inoculation.
    Sidorova LA; Alekseyeva AK
    Acta Virol; 1973 Jul; 17(4):293-7. PubMed ID: 4148208
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist).
    Chen Z; Aspelund A; Kemble G; Jin H
    Virology; 2006 Feb; 345(2):416-23. PubMed ID: 16289204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on influenza-virus virulence in recombinants between epidemic and vaccine strains.
    Zazimko LA; Vakin VS; Sklyanskaya EI; Zhdanov VM
    Acta Virol; 1987 Sep; 31(5):387-96. PubMed ID: 2891277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of the method of plaque formation of influenza virus and its application to neutralization tests.
    Kan T; Koyama K; Takaku K; Takahashi M; Kunita N
    Biken J; 1970 Sep; 13(3):185-92. PubMed ID: 4992055
    [No Abstract]   [Full Text] [Related]  

  • 19. Live viruses for immunization against influenza.
    Beare AS
    Prog Med Virol; 1975; 20():49-83. PubMed ID: 1105681
    [No Abstract]   [Full Text] [Related]  

  • 20. [Increase in the specific activity of killed influenza vaccines by using polyene antibiotics].
    Shneĭder MA; Shtil'bans EB; Paleĭ EI; Vil'ner LM; Tereshin IM
    Antibiotiki; 1981 Jul; 26(7):532-7. PubMed ID: 7271267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.